Orford, Keith
University of California, San Francisco · GlaxoSmithKline (United Kingdom) · Massachusetts General Hospital · Angeles Clinic and Research Institute · HealthONE · UCSF Helen Diller Family Comprehensive Cancer Center
3 papers on CoChat
Most cited papers
- Verified
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation
Orford, K. W., & Scadden, D. T. (2008) · Nature Reviews Genetics
Developmental Biology and Gene RegulationPluripotent Stem Cells Research
Cited by 851
- Verified
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways
Cited by 507
- Verified
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology
Melanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 158
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free